Cisapride (CAS 81098-60-4) is a gastroprokinetic agent that increases upper gastrointestinal motility by acting as a serotonin 5-HT₄ receptor agonist and enhancing acetylcholine release in the enteric nervous system. It has been used to manage gastro-oesophageal reflux disease (GERD) and gastroparesis by accelerating gastric emptying and improving oesophageal clearance.
Cisapride 81098-60-4 | Gastroprokinetic API Supplier & Manufacturer China from TCS GROUP is offered as a high-purity API for specialised markets, including veterinary medicine and restricted human use in regions where it remains authorised under strict conditions. Because of its history of cardiac safety concerns, particularly QT interval prolongation and risk of serious arrhythmias, many regulatory authorities have limited or withdrawn cisapride from general use in humans. This makes high-quality manufacturing control and accurate dosing especially critical.
Pharmacologically, cisapride’s promotility effect is valuable in conditions where delayed gastric emptying or reduced gastrointestinal motility compromise quality of life or complicate disease management. In veterinary practice, for example, cisapride is still used for feline megacolon and GI stasis in small animals when prescribed by veterinarians with appropriate monitoring.
Formulation work with cisapride typically involves oral solid dosage forms such as tablets and capsules, or compounded liquid preparations for specific patient groups. To support robust development, TCS INDUSTRIES LIMITED provides consistent API quality, detailed technical documentation and guidance on stability, impurity control and storage. Given the importance of dose precision and predictable release, formulators often work within a structured excipient framework from the same supplier, leveraging options available under the Active Pharmaceutical Ingredient and excipient ranges.
For companies building a gastrointestinal and cardiovascular product portfolio, internal cross-linking between related APIs can be strategically useful. Cisapride’s cardiac risk profile makes awareness of arrhythmia-related therapies important; within the same site, agents such as Amiodarone Hydrochloride 19774-82-4 and Atenolol 29122-68-7 illustrate the company’s presence in rhythm-control and antihypertensive segments, respectively.
An overview of how cisapride fits into the wider TCS GROUP product landscape can also be seen on the general Active Pharmaceutical Ingredient page, helping partners map their future GI and chronic-care pipelines. With its combination of technical support, regulatory awareness and integrated portfolio, TCS INDUSTRIES LIMITED is positioned to be a long-term partner for organisations that still require gastroprokinetic APIs under carefully controlled, evidence-based use conditions.